Literature DB >> 11502079

Diagnostic differences in social anhedonia: a longitudinal study of schizophrenia and major depressive disorder.

J J Blanchard1, W P Horan, S A Brown.   

Abstract

This study examined the hypothesis that, in schizophrenia, elevated trait social anhedonia (SA) is a stable individual difference, whereas in depression, increased SA is a reflection of a current clinical state that will diminish with recovery. Differences in trait Negative Affect (NA) and Positive Affect (PA) were also examined. Individuals with schizophrenia (n = 55) and depression (n = 34) were evaluated at baseline during hospitalization and compared with nonpsychiatric control participants (n = 41). Participants were assessed again at a 1-year follow-up. At baseline, compared with control participants, individuals with schizophrenia and depression were both characterized by elevated SA, greater NA, and lower PA. In schizophrenic individuals, elevated SA remained stable over the follow-up. However, in recovered depressed patients, SA declined over the follow-up period. Group differences remained in NA and PA over the 1-year follow-up. These results support the view that elevated SA is enduring in schizophrenia but that elevated SA is transiently related to clinical status in depression.

Entities:  

Mesh:

Year:  2001        PMID: 11502079     DOI: 10.1037//0021-843x.110.3.363

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  64 in total

1.  Schizotypal, schizoid and paranoid characteristics in the biological parents of social anhedonics.

Authors:  Alex S Cohen; Lindsay C Emmerson; Monica C Mann; Courtney B Forbes; Jack J Blanchard
Journal:  Psychiatry Res       Date:  2010-05-08       Impact factor: 3.222

Review 2.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

3.  Social Disconnection in Schizophrenia and the General Community.

Authors:  Michael F Green; William P Horan; Junghee Lee; Amanda McCleery; L Felice Reddy; Jonathan K Wynn
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  A dual change model of life satisfaction and functioning for individuals with schizophrenia.

Authors:  Melissa Edmondson; Rohini Pahwa; Karen Kyeunghae Lee; Maanse Hoe; John S Brekke
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

5.  Is social anhedonia related to emotional responsivity and expressivity? A laboratory study in women.

Authors:  Winnie W Leung; Shannon M Couture; Jack J Blanchard; Stephanie Lin; Katiah Llerena
Journal:  Schizophr Res       Date:  2010-12       Impact factor: 4.939

6.  Associations between trait anhedonia and emotional memory deficits in females with schizophrenia versus major depression.

Authors:  Emily K Olsen; Olivia A Bjorkquist; Anjuli S Bodapati; Stewart A Shankman; Ellen S Herbener
Journal:  Psychiatry Res       Date:  2015-09-09       Impact factor: 3.222

Review 7.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

Review 8.  The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs.

Authors:  Ann M Kring; Deanna M Barch
Journal:  Eur Neuropsychopharmacol       Date:  2014-01-22       Impact factor: 4.600

9.  Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia.

Authors:  Ivy F Tso; Tyler B Grove; Stephan F Taylor
Journal:  Schizophr Res       Date:  2010-01-03       Impact factor: 4.939

10.  Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder.

Authors:  Ivy F Tso; Tyler B Grove; Stephan F Taylor
Journal:  Psychiatry Res       Date:  2014-06-25       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.